Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Environmental Enteric Dysfunction
Interventions: TNIB Catheter; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cerebral Palsy (CP), Intelligibility, Speech, Augmentative and Alternative Communication
Interventions: AAC Speech supplementation; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 7 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Epilepsy, Seizure, Catamenial Epilepsy, Medically Resistant Epilepsy, Medically Resistant Seizures
Interventions: betaquik®; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • Madison, Wisconsin

Conditions: Bone Loss
Interventions: Bisphosphonate, Resistance Training/Bone-Loading Exercise, Placebo; Drug · Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 60 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado • Winston-Salem, North Carolina

Conditions: EGFR T790M Mutation Positive NSCLC
Interventions: AZD9291; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 32
States / cities: Anaheim, California • Beverly Hills, California • Burbank, California + 29 more

Conditions: Glioblastoma, Recurrent Glioblastoma
Interventions: Pembrolizumab, Olaparib, Temozolomide; Drug
Lead sponsor: L. Nicolas Gonzalez Castro, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York

Conditions: Major Depressive Disorder
Interventions: Ketamine, Psychotherapy; Drug · Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myelogenous Leukemia
Interventions: Fludarabine, Busulfan, Total Body Irradiation, Stem Cell Transplant; Drug · Radiation · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 55 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type2 Diabetes Mellitus
Interventions: BTI320, Placebo; Drug · Other
Lead sponsor: Boston Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Ventura, California • Albuquerque, New Mexico • Mt. Pleasant, South Carolina + 1 more

Conditions: Prostate Cancer
Interventions: Fermented Soy, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: New Haven, Connecticut • New London, Connecticut • Wakefield, Rhode Island

Conditions: Rapid Eye Movement Sleep Behavior Disorder
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Carcinoma, Benign Prostatic Hyperplasia
Interventions: Merit Medical Embospheres, Radiation Therapy; Device · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 50 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Anxiety, Depression
Interventions: Mindfulness Training for Primary Care; Behavioral
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 21 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Infertility
Interventions: Platelet rich plasma, Placebo; Combination Product
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Sunnyvale, California

Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions: BION-1301, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 28
States / cities: Birmingham, Alabama • Huntsville, Alabama • San Francisco, California + 24 more

Conditions: Atherosclerosis, High Blood Pressure, Type 2 Diabetes Mellitus, Heart Disease, Hypercholesterolemia
Interventions: Special Intervention; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 40 Years and older
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Advanced Microsatellite Stable Colorectal Cancer
Interventions: Denikitug, Nivolumab, Bevacizumab, Trifluridine-Tipiracil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: North Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 2 more

Conditions: Major Depressive Disorder
Interventions: Siemens 7T MRI, Sham Neurofeedback; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: Etanercept; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Pre-diabetes
Interventions: Peer-Led Lifestyle Education on Weight Loss; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Bladder (Urothelial, Transitional Cell) Cancer, Hematuria
Interventions: Headphones, Dwell time 5-10 minutes, Dwell Time more than 10 minutes; Device · Drug
Lead sponsor: Florian Schroeck; Federal
Eligibility: 18 Years and older
Enrollment: 1,740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina • Wilmington, North Carolina + 2 more

Conditions: Obstructive Sleep Apnea (OSA)
Interventions: Placebo oral capsule, DAW2020 oral capsule; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer, Cancer of the Prostate
Interventions: Low-count quantitative single-photon emission computed tomography imaging; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Decompensated Cirrhosis
Interventions: Methacetin Breath Test, Emricasan, Placebo oral capsule; Combination Product · Drug
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lakewood Rch, Florida

Search by objective public record fields.

OCT Guided Trans Nasal Imaging of the Small Intestine in Adults

Speech Production Enhancement Using Augmentative Communication for Kids

Medium Chain Triglycerides as an Adjunct to the Modified Atkins Diet for Women With Catamenial Epilepsy

Bone, Exercise, Alendronate, and Caloric Restriction

AZD9291 US Expanded Access Program

Surgical Pembro +/- Olaparib w TMZ for rGBM

Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression

Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia

Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes

Nutrition and Prostate Cancer

Sleep Profiles in REM Sleep Behavior Disorder

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Mindful Self-Regulation fMRI Study (MindfulPCfMRI)

Platelet Rich Plasma for Patients With Recurrent Implantation Failure

A Study of Zigakibart in Adults With IgA Nephropathy

Latinos Understanding the Need for Adherence

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression

Circadian RA Study in Rheumatoid Arthritis Subjects

Effectiveness Study of Community-Based, Peer-Led Education on Weight Loss and Diabetes

Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort (CystoDiscomfort)

DAW2020 on OSA Endotypic Traits

Low-Count Quantitative SPECT for Men Treated With Radium-223

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17